| CAS |
No.149402-51-7 |
| 英文名称 |
HPPH |
| 分子式 |
C39H48N4O4 |
| 分子量 |
636.82 |
| 溶解性 |
Soluble in DMSO ≥10mg/mL(Need ultrasonic) |
| 纯度 |
≥98% |
| 外观(性状) |
Light brown to black Soild |
| 储存条件 |
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL |
MFCD11040935 |
| SMILES |
CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6[C@H]([C@@H](C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C |
| InChIKey |
PUUBADHCONCMPA-USOGPTGWSA-N |
| InChI |
InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19，21，24，26，42，44H，8-16H2，1-7H3，(H，45，46)/t21-，24 ，26-/m0/s1 |
| PubChem CID |
148160 |
| 靶点 |
Others |
| 通路 |
Others |
| 背景说明 |
是一种photosensitizer。 |
| 生物活性 |
HPPH (Photochlor) is a second generation photosensitizer， which acts as a photodynamic therapy (PDT) agent.[1-2] |
| In Vitro |
Fluorescence image of 4T1 cells incubated with 0.49 μg/mL GO-PEG， 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 μM HPPH and 0.49 μg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 μM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact， the fluorescence of HPPH is rather weak[1]. |
| In Vivo |
Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity， while retaining effective control of primary tumor growth. To test this hypothesis， a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm2). Following illumination， mice are rested for 9 days; on the ninth day， mice are injected with HPPH. On day 10 following the first treatment， tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm2 given)[2]. |
| 细胞实验 |
4T1 cells are cultured in 96-well cell culture plates at 1×104/well for 24 h and then treated with GO-PEG-HPPH， HPPH， or GO-PEG at a series of concentrations (0.078125， 0.15625， 0.3125， 0.625， 1.25， 2.5， 5， 10， and 20 μM). Then， 20 μL of MTT solution (5.0 mg/mL) is added to each well. After the 4 h incubation with the MTT， the media are removed and 100 μL of DMSO is added to solubilize the formazan crystals. The cell toxicity efficacy is measured with a microplate reader at an absorbance of 570 nm[1]. |
| 动物实验 |
Mice[2]Tumor-bearing mice are injected in the tail vein with 0.4 μmol/kg HPPH or 5 mg/kg Porfimer sodium (PII)， followed 18-24 h later by illumination to a total light dose of 48 J/cm2 or 132 J/cm2 delivered at a light dose-rate of 14 mW/cm2. Control mice are treated with photosensitizer or light alone. Mice receiving a combination PDT regimen are treated initially with 0.4 μmol/kg HPPH or 5 mg/kg PII followed 18-24 h later by light dose of 48 J/cm2 given at 14 mW/cm2; 9 days later， mice are again injected with photosensitizer and tumors are illuminated with light at a dose of 132 J/cm2 given at 14 mW/cm2[2]. |
| 数据来源文献 |
[1]. Rong P， et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39.
[2]. Shams M， et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97. |
| 规格 |
1mg 5mg 10mg 25mg |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号